In this article, we examine the Orphan Drug Act with an eye toward its contribution to the public interest, using AIDS drugs to illustrate many of the central points. The major policy question is, How, if at all, can the act be used to meet the legislative goal of stimulating drug development for small patient populations without resulting in prices that make drugs inaccessible
The Orphan Drug Act encourages the development of products for rare diseases and conditions. Many co...
textabstractFor a significant number of patients, there exists no, or only little, interest in devel...
More than 10 years have been passed since the European Parliament approved a law to encourage pharma...
In this article, we examine the Orphan Drug Act with an eye toward its contribution to the public in...
The World Health Organization defines orphan diseases, as all pathological conditions, affecting 0....
The Orphan Drug Act (ODA) [1], first enacted in the United States in 1983, was set up to encourage t...
Orphan drugs and diseases are a neglected academic and scientific research area. The Orphan Drug Act...
ABSTRACT Rare diseases are a major public health problem and public health challenge. Orphan drugs ...
Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of MoldovaThe aim of t...
Putting aside whether diseases that affect only small numbers of people ( rare diseases ) should be ...
Background Rare diseases and neglected diseases are characterized by deficits in drug research and d...
A rare disease, or orphan disease, in the United States is a condition with a national prevalence of...
Journal ArticleIn 1983, Congress adopted the Orphan Drug Act (the "Act") pursuant to its power to re...
significant changes within the pharmaceutical industry regarding resources expended to develop produ...
Through the combined efforts of agencies and organizations in the public and private sector, drugs h...
The Orphan Drug Act encourages the development of products for rare diseases and conditions. Many co...
textabstractFor a significant number of patients, there exists no, or only little, interest in devel...
More than 10 years have been passed since the European Parliament approved a law to encourage pharma...
In this article, we examine the Orphan Drug Act with an eye toward its contribution to the public in...
The World Health Organization defines orphan diseases, as all pathological conditions, affecting 0....
The Orphan Drug Act (ODA) [1], first enacted in the United States in 1983, was set up to encourage t...
Orphan drugs and diseases are a neglected academic and scientific research area. The Orphan Drug Act...
ABSTRACT Rare diseases are a major public health problem and public health challenge. Orphan drugs ...
Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of MoldovaThe aim of t...
Putting aside whether diseases that affect only small numbers of people ( rare diseases ) should be ...
Background Rare diseases and neglected diseases are characterized by deficits in drug research and d...
A rare disease, or orphan disease, in the United States is a condition with a national prevalence of...
Journal ArticleIn 1983, Congress adopted the Orphan Drug Act (the "Act") pursuant to its power to re...
significant changes within the pharmaceutical industry regarding resources expended to develop produ...
Through the combined efforts of agencies and organizations in the public and private sector, drugs h...
The Orphan Drug Act encourages the development of products for rare diseases and conditions. Many co...
textabstractFor a significant number of patients, there exists no, or only little, interest in devel...
More than 10 years have been passed since the European Parliament approved a law to encourage pharma...